Jeffery Kasher

DURHAM, N.C. - June 2, 2022 - (Newswire.com)

Pro-ficiency, a pioneer in the field of simulation-based training in clinical trials, has opened up a select number of seats on the Company's Board of Directors. Dr. Jeffrey Kasher, a renowned visionary in clinical trials with over 28 years of experience at organizations like Eli Lilly, is the first to join as the newest Director. 

Dr. Kasher is known to be a driving force behind innovation in clinical trials. From being an early and consistent advocate of the importance of patient engagement while President of Patients Can't Wait to serving on the board of - and advisor to - some of the most impactful organizations in clinical research, Kasher is a visionary leader and a change agent. 

"Jeff is the King of clinical trial innovation, so saying we are thrilled that he has joined our Board is an understatement. We believe that Pro-ficiency can have one of the most profound impacts on clinical trials by turning decisions into data. With Jeff's insights and advice, we can finally change what this industry has come to accept from their training," said Pro-ficiency President and Founder, Dave Hadden. "Jeff only dedicates his time to efforts that move the needle and the fact that he has chosen to hop on this rocket ship of ours speaks volumes."

"At first, the concept of simulation-based training in clinical trials was interesting, but once I fully understood the power of the solution to de-risk studies, I knew I wanted on board," said Dr. Kasher. "It is both a unique approach to a ubiquitous element of study start-up but an elegantly simple one as well. It's rare that I see a solution that solves problems without adding layers of complexity for sites." 

Currently, Jeff serves as the President of Patients Can't Wait, and is an Advisory Board member for Be the Partner, BlueCloud, and Wake Forest masters in clinical research management program. He advises several multinational Pharmaceutical companies and CROs, and emerging technology companies, and serves on the Board of Catalyst Clinical Research. He has been named one of the CenterWatch "20 Innovators Changing the Face of the Clinical Trials Industry."

Jeff received a B.S. in Chemistry from Franklin & Marshall College, a Ph.D. in Pharmacology from the State University of New York, and a Post-Doctoral fellowship in Physiology at Yale University School of Medicine.

About Pro-ficiency

Pro-ficiency is a leading provider of simulation-based training and compliance solutions for clinical trials. The Company provides a comprehensive suite of services, including turn-key customized virtual training simulations, training and compliance monitoring tools, and real-time data & predictive analytics. Learn more at pro-ficiency.com.

Press Release Service by Newswire.com

Original Source: Dr. Jeffrey Kasher Joins Pro-Ficiency Board of Directors